A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of BG-60366 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
Phase 1
Recruiting
- Conditions
- EGFR-Mutant Non-Small Cell Lung Cancer
- Registration Number
- 2024-517322-26-00
- Lead Sponsor
- Beigene Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised, recruiting
- Sex
- Not specified
- Target Recruitment
- 13
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Not specified
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (7)
Universitaetsklinikum Ulm AöR
🇩🇪Ulm, Germany
Fondazione IRCCS San Gerardo Dei Tintori
🇮🇹Monza, Italy
Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
🇮🇹Bologna, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
🇮🇹Rome, Italy
Hospital Universitario Puerta De Hierro De Majadahonda
🇪🇸Majadahonda, Spain
Hospital Universitario 12 De Octubre
🇪🇸Madrid, Spain
Hospital Universitari Vall D Hebron
🇪🇸Barcelona, Spain
Universitaetsklinikum Ulm AöR🇩🇪Ulm, GermanyEugen TauschSite contact073150045729eugen.tausch@uniklinik-ulm.de